---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-23-000012"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T17:53:13.175200+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biogen posts Q1 GAAP EPS $2.67, non-GAAP $3.40; reaffirms FY23 guidance; multiple regulatory milestones

## Summary
- Q1 revenue $2,463M (-3% YoY); GAAP EPS $2.67 (+30%); Non-GAAP EPS $3.40 (-6%).
- LEQEMBI Alzheimer's drug: FDA Accelerated Approval, traditional filing Priority Review; PDUFA July 6, 2023.
- Zuranolone depression NDA accepted with Priority Review; PDUFA Aug 5, 2023.
- Tofersen SOD1-ALS PDUFA date April 25, 2023; Advisory Committee backed surrogate endpoint.
- Appointed Chuck Triano (IR) and Adam Keeney (Corporate Dev); cost optimization program initiated.

## SEC filing metadata
- accession: 0000875045-23-000012
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504523000012/0000875045-23-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504523000012/biib-20230425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-23-000012
- JSON: https://secwatch.observer/filing/0000875045-23-000012.json
- Plain text: https://secwatch.observer/filing/0000875045-23-000012.txt

## Key facts
- Earnings Releases
  BIOGEN INC. reported first quarter ended March 31, 2023 results: revenue $2,463 million, EPS $2.67. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $2,463 million
  - EPS: $2.67
  - Guidance: reaffirmed
  - Result: reported results
  source text: three potential launches in 2023; Company reports first quarter 2023 results and reaffirms full year 2023 guidance First quarter 2023 financial results • First quarter revenue $2,463 million; GAAP diluted EPS $2.67; Non-GAAP diluted EPS $3.40 Poised for leadership in Alzheimer’s disease (AD) with LEQEMBI and BIIB080 • LEQEMBI (lecanemab-irmb) FDA Accelerated
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504523000012/0000875045-23-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.